Ambene® Bio (Solution) Instructions for Use
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Deko Company, LLC (Russia)
Or
Biokhimik, JSC (Russia)
Contact Information
PROMOMED RUS LLC (Russia)
ATC Code
M09AX (Other drugs for the treatment of musculoskeletal system diseases)
Dosage Form
| Ambene® Bio | Solution for injection 0.1 g/1 ml: 1 ml or 2 ml amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection colorless or from light yellow to light brownish-yellow.
| 1 ml | |
| Bioactive extract from small marine fish | 0.1 g |
Excipients : phenol – up to 0.005 g/ml, water for injection – up to 1 ml.
1 ml – ampoules of light-protective glass (5) – contour cell packs made of polyvinyl chloride film (1) complete with an ampoule knife, scarifier or without – cardboard boxes.
1 ml – ampoules of light-protective glass (5) – contour cell packs made of polyvinyl chloride film (2) complete with an ampoule knife, scarifier or without – cardboard boxes.
2 ml – ampoules of light-protective glass (5) – contour cell packs made of polyvinyl chloride film (1) complete with an ampoule knife, scarifier or without – cardboard boxes.
2 ml – ampoules of light-protective glass (5) – contour cell packs made of polyvinyl chloride film (2) complete with an ampoule knife, scarifier or without – cardboard boxes.
Clinical-Pharmacological Group
Tissue repair stimulant of natural origin
Pharmacotherapeutic Group
Tissue repair stimulant of natural origin
Pharmacological Action
Ambene® Bio is a chondroprotector, the active component of which is a bioactive extract from small marine fish.
The extract contains mucopolysaccharides (chondroitin sulfate), amino acids, peptides, and ions of sodium, potassium, calcium, magnesium, iron, copper, and zinc.
Ambene® Bio prevents the destruction of the macromolecular structures of normal tissues and stimulates recovery processes in the interstitial tissue and articular cartilage tissue, which explains its analgesic effect.
The anti-inflammatory effect and tissue regeneration are based on the inhibition of hyaluronidase activity and the normalization of hyaluronic acid biosynthesis.
Both these effects are synergistic and cause the activation of restorative processes in tissues (in particular, the restoration of cartilage structure).
Indications
In adults
- Primary and secondary osteoarthrosis of various locations (coxarthrosis, gonarthrosis, arthrosis of small joints);
- Osteochondrosis;
- Spondylosis.
ICD codes
| ICD-10 code | Indication |
| M15 | Polyosteoarthritis |
| M16 | Coxarthrosis [arthrosis of the hip joint] |
| M17 | Gonarthrosis [arthrosis of the knee] |
| M19.9 | Unspecified arthrosis |
| M42 | Spinal osteochondrosis |
| M47 | Spondylosis |
| ICD-11 code | Indication |
| FA00.Z | Osteoarthritis of hip, unspecified |
| FA01.Z | Osteoarthritis of knee, unspecified |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA8Z | Degenerative disease of spine, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For polyosteoarthrosis and osteochondrosis, the drug is administered deep intramuscularly
- 1 ml/day, the course of treatment is 20 injections (1 injection per day for 20 days)
Or
- 2 ml every other day, the course of treatment is 10 injections (1 injection every other day for 20 days).
For predominant involvement of large joints, the drug is administered intra-articularly, 1-2 ml into each joint with an interval of 3-4 days. A total of 5-6 injections per joint per course.
A combination of intra-articular and intramuscular administration methods is possible.
It is advisable to repeat the course of treatment after 6 months following consultation with a doctor.
Adverse Reactions
The frequency of adverse reactions listed below was determined according to the following gradation: very common (>1/10), common (>1/100, ≤1/10), uncommon (>1/1000, ≤1/100), rare (>1/10000, ≤1/1000), very rare (≤1/10000).
Allergic reactions : rare – itching; very rare – anaphylactic reactions.
Local reactions rare – skin redness and burning sensation at the injection site.
Other short-term myalgia. In some cases, with intra-articular injections, a transient increase in pain syndrome is possible.
Contraindications
- Hypersensitivity to the components of the drug;
- Pregnancy;
- Lactation period;
- Children under 18 years of age (due to the lack of scientific clinical data in this category of patients).
Use in Pregnancy and Lactation
The use of the drug is contraindicated during pregnancy and breastfeeding.
Pediatric Use
Use in children and adolescents under 18 years of age is contraindicated.
Special Precautions
In case of individual intolerance to seafood (marine fish), the risk of developing allergic reactions increases.
Effect on the ability to drive vehicles and mechanisms
The use of the drug does not affect the ability to perform potentially hazardous activities that require increased concentration and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, work of a dispatcher and operator).
Overdose
In case of overdose, dose-dependent undesirable drug reactions are intensified.
Drug Interactions
None identified to date.
Storage Conditions
The drug should be stored out of the reach of children at a temperature from 15°C (59°F) to 25°C (77°F) in the secondary packaging (box).
Shelf Life
Shelf life – 2 years. Do not use after the expiration date printed on the packaging.
Dispensing Status
The drug is dispensed by prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer